Yoshihisa Kobayashi

Yoshihisa Kobayashi

Auto-generated profile, based on publicly available information

Yoshihisa Kobayashi

Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo 104-0045, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CTCiric To
Ciric To
TBTyler S. Beyett
Tyler S. Beyett
JJJaebong Jang
Jaebong Jang
WFWilliam Feng
William Feng
MBMagda Bahcall
Magda Bahcall
PJPasi Antero Jänne
Pasi Antero Jänne

1 January 2014 in Lung Cancer
Verified
Journal Article
Closed access
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
YSYukinori Sakao
Yukinori Sakao
GDGautam A. Deshpande
Gautam A. Deshpande
TFTakayuki Fukui
Takayuki Fukui
HKHiroaki Kuroda
Hiroaki Kuroda
TMTetsuya Mitsudomi
Tetsuya Mitsudomi

2 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
CCChhayheng Chhoeu
Chhayheng Chhoeu
JLJiaqi Li
Jiaqi Li
KPKristin S. Price
Kristin S. Price
LKLesli A. Kiedrowski
Lesli A. Kiedrowski
PJPasi Antero Jänne
Pasi Antero Jänne

6 September 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
RYRyohei Yoshida
Ryohei Yoshida
MSMaria Saigi
Maria Saigi
TTTetsuo Tani
Tetsuo Tani
BSBenjamin F. Springer
Benjamin F. Springer
HSHirofumi Shibata
Hirofumi Shibata
DBDavid A Barbie
David A Barbie
Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI–resistant cells. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI–resistant cells. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI–resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Significance: MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment.

24 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
ECElizabeth F. Cohen
Elizabeth F. Cohen
NMNavin R. Mahadevan
Navin R. Mahadevan
JAJoao V. Alessi
Joao V. Alessi
PJPasi Antero Jänne
Pasi Antero Jänne
The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer. By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative resistance-causing fusion oncogene, we identify patients who benefit and those who do not from this treatment approach. Through evaluation including RNA-seq of potential drug resistance-imparting fusion oncogenes in 504 patients with EGFR mutant lung cancer, we identify only a minority of them as functional, potentially capable of imparting EGFR inhibitor resistance. We further functionally validate fusion oncogenes in vitro using CRISPR-based editing of EGFR mutant cell lines and use these models to identify known and unknown drug resistance mechanisms to combination therapies. Collectively, our results partially reveal the complex nature of fusion oncogenes as potential drug resistance mechanisms and highlight approaches that can be undertaken to determine their functional significance.

20 April 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ACAlissa J. Cooper
Alissa J. Cooper
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
DKDewey Kim
Dewey Kim
SCSarah E. Clifford
Sarah E. Clifford
SKSasha Kravets
Sasha Kravets
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
Purpose: We pursued genomic analysis of an exceptional responder with non–small cell lung cancer (NSCLC) through a multi-platform effort to discover novel oncogenic targets. Experimental Design: In this open-label, single-arm phase II study (NCT01829217), an enriched cohort of patients with advanced NSCLC was treated with the multi-kinase inhibitor sunitinib. The primary endpoint was objective response rate. Tissue was collected for multi-platform genomic analysis of responders, and a candidate oncogene was validated using in vitro models edited by CRISPR-Cas9. Results: Of 13 patients enrolled, 1 patient (8%), a never smoker, had a partial response lasting 33 months. Genomic analysis of the responder identified no oncogenic variant using multi-platform DNA analysis including hotspot allelotyping, massively parallel hybrid-capture next-generation sequencing, and whole-exome sequencing. However, bulk RNA-sequencing (RNA-seq) revealed a novel fusion, TMEM87A–RASGRF1, with high overexpression of the fusion partners. RASGRF1 encodes a guanine exchange factor which activates RAS from GDP-RAS to GTP-RAS. Oncogenicity was demonstrated in NIH/3T3 models with intrinsic TMEM87A–RASGRF1 fusion. In addition, activation of MAPK was shown in PC9 models edited to express this fusion, although sensitivity to MAPK inhibition was seen without apparent sensitivity to sunitinib. Conclusions: Sunitinib exhibited limited activity in this enriched cohort of patients with advanced NSCLC. Nonetheless, we find that RNA-seq of exceptional responders represents a potentially underutilized opportunity to identify novel oncogenic targets including oncogenic activation of RASGRF1.